{"id":636,"date":"2024-03-14T08:15:30","date_gmt":"2024-03-14T08:15:30","guid":{"rendered":"https:\/\/genes2me.com\/blog\/?p=636"},"modified":"2024-03-14T12:31:39","modified_gmt":"2024-03-14T12:31:39","slug":"revolutionizing-cancer-diagnosis-with-g2ms-liquid-biopsy-ngs-clinical-panels","status":"publish","type":"post","link":"https:\/\/genes2me.com\/blog\/2024\/03\/14\/revolutionizing-cancer-diagnosis-with-g2ms-liquid-biopsy-ngs-clinical-panels\/","title":{"rendered":"Revolutionizing Cancer Diagnosis with G2M’s Liquid Biopsy NGS Clinical Panels"},"content":{"rendered":"\n
\"\"
Cancer Diagnosis Solution<\/figcaption><\/figure>\n\n\n\n

In the realm of cancer diagnosis and treatment, the advent of liquid biopsy has sparked a transformative shift. Liquid biopsy, a term encompassing the collection and analysis of non-solid biological tissues primarily from peripheral blood, offers a non-invasive yet highly effective means of detecting disease-associated biomarkers. This revolutionary technique utilizes circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) as sample materials, providing crucial insights into cancer detection, treatment selection, therapy response monitoring, and resistance mechanisms exploration.<\/p>\n\n\n\n

Liquid biopsy’s appeal lies in its accessibility and reduced patient complications compared to traditional surgical biopsies. By analyzing bodily fluids such as blood, urine, saliva, pleural effusion, and cerebrospinal fluid, liquid biopsy offers a non-aggressive approach to detecting disease-associated biomarkers. Among these bodily fluids, blood emerges as the most commonly utilized medium due to its rich source of circulating extracellular nucleic acids and tumor-derived materials.<\/p>\n\n\n\n

Through next-generation sequencing<\/a><\/strong> (NGS), liquid biopsy enables the detailed molecular analysis of ctDNA, cfDNA, and CTCs. This sophisticated technology facilitates the identification of specific mutations and biomarkers, guiding treatment decisions and predicting therapeutic responses.<\/p>\n\n\n\n

The FDA’s approval of diagnostic tests underscores the growing recognition of liquid biopsy’s clinical utility, offering valuable prognostic information and personalized treatment recommendations.<\/p>\n\n\n\n

Liquid biopsy’s versatility extends across various clinical applications, including disease screening<\/a><\/strong>, patient stratification, therapy selection, treatment response monitoring, and detection of minimal residual disease. By harnessing the power of CTC and cfDNA detection technologies, liquid biopsy empowers clinicians to tailor treatment strategies at different stages of cancer diagnosis and management.<\/p>\n\n\n\n

Key Features<\/h2>\n\n\n\n
\"\"<\/figure>\n\n\n\n

Benefits of ctDNA Liquid biopsy<\/strong><\/h3>\n\n\n\n